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Abstract
Patients with cervical carcinoma (CC) are frequently immunocompromised. Dendritic cells (DCs) are potent antigen-
presenting cells. Using multicolor flow cytometry, the percentages of CD11c+ (DC1) and CD123+ (DC2) subsets, were 
determined in the peripheral blood of 37 patients with cervical carcinoma (CC), 54 patients with CIN, and 62 healthy 
individuals. A substantial reduction of circulating dendritic cells and accordingly immunodepression may be associated 
with increased IL-6 and TGF-β in serum. These findings could give expression to the immunosuppression of circulating 
dendritic cells in patients with CC and CIN, thus, may indicate novel aspects of cervical carcinoma immune evasion.
Introduction
Cervical carcinoma (CC) is the second most common
cancer among women worldwide. Approximately 371,200
new cases are diagnosed each year, and nearly 200,000
deaths are attributable to the disease [1-4]. Cervical carci-
noma and its precursor lesions, cervical intraepithelial
neoplasia (CIN), are virus-related neoplasms. As such,
their initiation and promotion is associated with persis-
tent infection by oncogenic human papillomavirus (HPV)
[5,6]. Although early stage cervical carcinoma can be
cured by radical surgery or radiotherapy with similar
e f f e c t i v e n e s s  [ 7 ] ,  u p  t o  3 5 %  o f  p a t i e n t s  w i l l  d e v e l o p
advanced metastatic disease [8] for which treatment
results are poor. Immunotherapeutic agents may provide
a novel therapeutic strategy for the treatment of recur-
rent and metastatic disease. Cervical carcinoma patients
obviously fail to mount an efficient cytotoxic T cell
response against HPV antigens. This is probably due to
low expression levels of both viral protein and MHC mol-
ecules [9,10] as well as to lack of costimulatory molecules
crucial for naive T cell priming by the tumor cells [11].
For these reasons, current research aims to develop more
efficient immunotherapy to stimulate an antitumor
immune response. In this context, one approach toward
developing an effective immunotherapeutic regime for
cervical carcinoma may be through the manipulation of
antigen-presenting cells, such as dendritic cells (DCs).
DCs are potent, professional antigen-presenting cells
which can initiate a primary immune response to anti-
gens by naive T cells [12]. Several lines of evidence sug-
gest that DCs loaded with various tumor antigens, such
as tumor fragments or antigen peptides, or with antigen
genes by way of retrovirus or adenovirus vectors, are
capable of activation and expansion of tumor-specific T
cells in vitro [5,13-15]. To date, only a few clinical trials of
DC vaccination have been reported in cancer patients,
with disappointing results. In addition to the immunode-
ficiency of the patients, several other limitations are cur-
rently hindering the potential of this technique, including
attaining pure DCs, loading the DCs with tumor antigen,
and transducing the DCs with tumor genes [5,14,16-18].
DCs, as the most potent antigen presenting cells, play a
central role in the initiation and regulation of immune
responses, Which are detected using multicolor flow
cytometry, electron microscope or immunocytochemis-
tryImmunocytochemistry Immunocytochemistry Immu-
nocytochemistry and so on. However, human DCs are
not a homogenous population. Besides inducing anti-
tumor immunity, DCs can induce tumor-special anergy
or tolerance [18-21]. DCs originate from CD34+
hematopoietic stem cells (HSC). Myeloid dendritic cells
(DC1) and plasmacytoid DCs (DC2) are the two principal
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subpopulations of human DCs, and their characteristics
vary greatly in phenotype, migration, and function. DC1
cells are effective T cell stimulators, inducing a tumor
specific immune response; however, the function of DC2
cells is uncertain. They not only stimulate tumor specific
immune responses, they also contribute to tumor
immune tolerance. It has been suggested that
CD11c+DC1 cells primarily induce Th1 differentiation,
whereas DC2 cells, which express the receptor for IL-3
(CD123), mainly promote a Th2 response. Many studies
indicate that in a tumor microenvironment, DCs both
decrease in quantity and are impaired in function. Both
DC populations were significantly lower in patients with
cancer than in healthy donors [22-25]. DC subsets may be
used differentially in immune responses to various anti-
gens, including tumor-associated antigens. However, lit-
tle is known about the frequency or function of these two
subsets of DCs in cervical carcinoma patients.
Tumors lack specific antigens and can hide or change
their antigens to escape immune surveillance. They can
also manipulate dendritic cell subset distributions and
subvert tumor immunity by secreting inhibitory cytok-
ines such as IL-2, IL-4, IL-10, IL-6, TFG-β, VEGF, and
IFN-γ. Some of these are produced by human tumor cells
themselves, whereas others are not only produced by
tumor cells but also induced systemically by tumor cell-
derived products. TGFβ acts as a stimulator of tumor
invasion by promoting extracellular matrix production
and angiogenesis, stimulating tumor proliferation, and
inhibiting host immune functions [26]. IL-6 has an
immunosuppressive role in cancer patients by inhibiting
the development of DCs [27]. VEGF is a strong mitogen
for endothelial cells and raises vascular permeability; it
takes part in the neovascularization of the tumor tissue
[28]. Elevated IL-10 concentrations in serum contribute
to an impaired antitumor immune response [29]. These
cytokines may directly or indirectly affect the function of
DCs.
In the current study, we want to know the change of
subsets of DCs in CC and the health. And we hope to get
the message from the trend. we investigated the propor-
tions of these two DC subsets in the peripheral circula-
tion of 37 patients with cervical carcinoma, 54 patients
with CIN, and 62 healthy individuals using multicolor
flow cytometry. We detected the expression of CD123,
CD11c, HLA-DR, CD80 and CD86 on the surface of DCs.
We also investigated the levels of the cytokines IL-10, IL-
6, TFG-β, and VEGF in serum to examine the claim that
the low proportion and impaired maturity of freshly iso-
lated dendritic cell subsets from patients with cervical
cancer correlates with increased levels of cytokines in
their serum.
Materials and methods
Patients
All patients were from the Women's Hospital School of
Medicine at Zhejiang University (Hangzhou, China) with
histologically confirmed primary cervical carcinoma and
were recruited between June 2006 and May 2007. All the
patients have no prior therapy restrictions including sur-
gery chemiotherapy and radiotherapy. All the patients
have no other complications, so their vital sign and basic
lab tests are normal. The stages of all CIN patients sele-
tected are CINI-III. The stages of all CC patients sele-
tected are early stage(Ia1 to Ib2). Controls were randomly
selected from healthy women seen for gynecologic exam-
inations at the Women's Hospital School of Medicine at
Zhejiang University during the period when women with
cervical cancer and CIN were enrolled. Control selection
criteria included no positive findings during the gyneco-
logical examination, no history of cancer, age matching to
the patients and residence in Zhejiang Province. A total
of 90 patients were studied, 37 with cervical carcinoma
and 58 with CIN including 54 CINII-III and 4 CINI. For
too few CINI, they were not being statistics. All women
included in the study provided written informed consent.
Flow Cytometry Analysis
2 ml peripheral blood (PB) were taken into heparinized
tubes (sodium heparin). Peripheral blood mononuclear
cells (PBMCs) were isolated by density gradient centrifu-
gation on Lymphoprep (Amersham Bioscience, Sweden)
for 25 min at 600 g at room temperature. PBMCs were
collected and washed twice in phosphate-buffered saline.
The cells were stained using the following antibodies:
anti-CD11c-FITC, anti-CD123-PE, anti-HLA-DR-PE-
Cy5, anti-CD80-FITC, and anti-CD86-PE. Respective
IgG isotype controls were run for each specimen. Isolated
cells (5 × 105) were incubated for 30 min at 4°C with
monoclonal antibodies specified against surface antigens
and washed twice in PBS containing 0.2 mm ethylenedi-
aminetetraacetic acid (EDTA) and 0.5% bovine serum
albumin (BSA). Freshly isolated peripheral blood mono-
nuclear cells were analyzed by flow cytometry for quanti-
tation and immunophenotyping of dendritic cell subsets.
The data were analyzed using Cell Quest software (Bec-
ton Dickinson, San Jose, California, USA). The myeloid
DCs (DC1) were identified as a population of mononu-
clear cells expressing CD11c+, but without expression of
CD123. Lymphoid DCs (DC2) were identified as
CD123+, but without expression of CD11c.
ELISA
Sera from 37 patients with cervical cancer, 54 patients
with CINII-III and 62 controls were collected for
cytokine quantitation. Concentrations of serum IL-6, IL-Ye et al. Journal of Experimental & Clinical Cancer Research 2010, 29:78
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10, VEGF and TGF-β were measured by ELISA according
to the manufacturerâ€™s instruction (BD Biosciences,
San Diego, CA). The assay sensitivities for IL-6, IL-10,
VEGF and TGF-β are 2 pg/ml, 19 pg/ml, 5 pg/ml and 15.6
pg/ml. All assays were conducted in duplicate.
Statistical Analysis
Statistical analysis was performed by ANOVA with Bon-
ferroni modification. Differences were considered signifi-
cant at p values < 0.05.
Results
Dendritic cell subsets in patients and controls
In this study we detected both myeloid (CD11c+) and
lymphoid (CD123+) cells in peripheral blood of women
with cervical carcinoma or CINII-III and in controls. The
proportions of dendritic cell subsets are given in Table 1
and Figure 1, Figure 2. In patients with cervical carci-
noma, DC1 constituted 7.00 ± 5.49% of total PB mononu-
clear cells; in CINII-III they were 15.38 ± 13.63%, and in
controls they were 21.22 ± 17.69%. The percentage of
DC1 was significantly lower (P < 0.05) in patients with
cervical carcinoma than in the CIN and control groups.
There were no significant differences (P > 0.05) in the
percentage of DC1 between the CIN groups and the con-
trols.
In patients with cervical carcinoma, DC2 constituted
0.67 ± 0.484% of total PB mononuclear cells; in women
with CINI-III they were 1.17 ± 1.14%, and in controls
they were 1.14 ± 0.75%. The percentage of DC2 was sig-
nificantly lower (P < 0.05) in patients with cervical carci-
noma than in the control group. The percentage of DC2
was not significantly different (P > 0.05) between patients
with cervical carcinoma and the CIN group. There were
also no significant differences (P > 0.05) in the percentage
of DC2 between the CIN groups and the controls. We
found that the proportions of DC2 were lower in patients
with cervical carcinoma in comparison with the CIN and
the controls; the CIN and the controls were almost equiv-
alent.
The variation of surface markers in DCs of patients with CC, 
CIN and controls
T o further characterize DCs in cancer patients, we next
determined their expressions of the surface markers
HLA-DR, CD80, and CD86 by flow cytometry. The
expressions of these antigens are shown in Table 2 and
Figure 3. We found the HLA-DR expression in the CIN
group (48.09 ± 16.07%) was higher than that in the
healthy individuals (42.70 ± 17.53%) and highest in
patients with cervical carcinoma (60.59 ± 14.64%). It was
significantly higher (P < 0.05) in the CC group compared
to the CIN group and the controls. But no significant dif-
ferences (P > 0.05) between the CIN groups and the con-
trols were observed.
We also detected the expression of CD80 and CD86 on
the surface of DCs. The expression of CD80 and CD86 in
the CIN group (CD80: 49.52 ± 21.74%; CD86: 46.92 ±
15.24%) was lower than that of the healthy individuals
(CD80: 51.23 ± 17.16%; CD86: 49.02 ± 21.58%), and low-
est in patients with cervical carcinoma (CD80: 39.59 ±
17.39%; CD86: 42.54 ± 19.51%). There was significantly
lower (P < 0.05) CD80 expression in the CC groups than
in the controls, and also significantly lower expression (P
< 0.05) in the CC group than in the CIN group. But no
significant differences (P > 0.05) between the CIN groups
and the controls were observed. There were no signifi-
cant differences in CD86 between any groups. DCs from
the peripheral blood of cancer patients thus exhibit
decreased expression of these costimulatory molecules as
compared to controls.
Cytokine secretion in CC, CIN and controls
We next investigated cytokine secretion in patients with
CC and CIN compared to controls. The levels of these
cytokines are shown in Table 3and Figure 4, Figure 5.
Table 1: The percentage of DC1 and DC2 in patients with CC, CINII-III and controls
Normal (n = 62) CINII-III (n = 54) CC (n = 37) P
CD11c+(DC1) 21.22 ± 17.69 15.38 ± 13.63 7.00 ± 5.49 0.096* 0.000** 0.000***
CD123+(DC2) 1.14 ± 0.75 1.17 ± 1.14 0.67 ± 0.484 0.392* 0.012** 0.087***
*Normal vs CINII~III; ** Normal vs CC; *** CINII~III vs CC
P of the three groups: CD11c+(DC1): P = 0.000, F = 16.839; CD123+(DC2): P = 0.042, F = 3.248
Figure 1 The percentage of DC1 in patients with CC, CIN and con-
trols.
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Women with CIN (18.19 ± 12.58 pg/mL) had significantly
higher IL-6 levels in their peripheral blood than did con-
trols (11.29 ± 6.36 pg/mL); IL-6 levels were highest in
women with CC (23.67 ± 11.36 pg/mL). There were sig-
nificant differences between any two groups.
Similar observations were found for TGF-β. The level
of TGF-β in the CIN group (6.41 ± 5.20 pg/mL) was
higher in comparison to the healthy individuals (5.60 ±
4.83 pg/mL) and highest in patients with cervical carci-
noma (18.22 ± 12.18 pg/mL). It was significantly higher
(P < 0.05) between the CC groups and the controls. It was
also significantly higher (P < 0.05) between the CC
groups and the CIN group. But no significant differences
(P > 0.05) between the CIN groups and the controls were
observed.
No obvious variation was observed in levels of IL-10
and VEGF. The levels of IL-10 and VEGF in the CIN
group (IL-10: 57.95 ± 32.94 pg/mL; VEGF: 27.92 ± 19.13
pg/mL) were higher in comparison to the healthy individ-
uals (IL-10: 52.69 ± 28.27 pg/mL; VEGF: 25.54 ± 19.13
pg/mL) and highest in patients with cervical carcinoma
(IL-10: 60.18 ± 29.92 pg/mL; VEGF: 30.39 ± 24.19 pg/
mL). There were no significant differences between any
two groups.
Patients with CC and CIN thus have higher levels of
these suppressive cytokines than the controls.
Discussion
The ability of tumor cells to evade host immune system
control can be ascribed to many mechanisms, including
deletion of tumor-specific cytotoxic T-lymphocytes and
recruitment of regulatory T-lymphocytes and inhibitory
c e l l  t y p e s .  I n  a d d i t i o n ,  c a n c e r  p a t i e n t s  m a y  p r e s e n t  a
defect in the host immune system [4,30,31]. One of the
targets of this defect is represented by professional APC;
an impaired DC function in cancer patients has been
reported by several groups [32-34]. Tumors achieve this
suppressive effect on DC by secreting tumor-derived fac-
tors, as recently described [27,29,35]. Human DCs are
phenotypically and functionally heterogeneous. The abil-
ity to identify and enumerate DCs and their subsets in
tumor tissue and in the peripheral circulation of patients
with cancer appears to be fundamental for the under-
standing of the role of these cells in the host antitumor
responses.
Firstly, we showed that patients with cervical carci-
noma and CIN exhibit a significant decrease in the abso-
lute number of circulating DCs when compared to
healthy controls. The reduction affects both of the two
main subsets of DCs circulating in the PB. The most
striking observation of the current study was a relative
decrease in the percentage of CD11c+DC cells (DC1) in
the peripheral circulation of CC patients. The percentage
of DC1 was significantly lower (P < 0.05) in patients with
cervical carcinoma than in the CIN and control groups.
This is in agreement with other studies [23,24,36].
Secondly, we also found that the proportions of
CD123+DC cells (DC2) were lower in patients with cervi-
cal carcinoma in comparison with the CIN and the con-
trols; the CIN and the controls were almost equivalent,
and there was not significantly different (P > 0.05)
between the CC and the CIN. It is seemed that DC2 do
not decrease noticeably in the CIN, although they were
decreased in the CC like DC1.
As the classic antitumor cells, DC1 were induced to
apoptosis by tumor if there was no tumor intervention or
enhancement of DC1. The loss of DC1 thus correlates
with tumor burden. DC2 possessing both antitumor and
Figure 2 The percentage of DC2 in patients with CC, CIN and con-
trols.
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Table 2: The functional immunophenotypings of DCs in patients with CC, CINII-III and controls
Normal (n = 62) CINII-III (n = 54) CC (n = 37) P
HLA-DR 42.70 ± 17.53 48.09 ± 16.07 60.59 ± 14.64 0.082* 0.000** 0.001***
CD80 51.2 3 ± 17.16 49.52 ± 21.74 39.59 ± 17.39 0.633* 0.004** 0.017***
CD86 49.02 ± 21.58 46.92 ± 15.24 42.54 ± 19.51 0.803* 0.157** 0.111***
*Normal vs CINII~III; ** Normal vs CC; *** CINII~III vs CC
P of the three groups: HLA-DR: P = 0.000, F = 13.634; CD80: P = 0.012, F = 4.587;
CD86: P = 0.241, F = 1.438Ye et al. Journal of Experimental & Clinical Cancer Research 2010, 29:78
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immunosuppression displayed a little differently in pro-
cess of tumor. The side of immunosuppression may per-
mit or promote the development of tumor [33,34].
Our findings indicate that, in cervical carcinoma
patients, decreased numbers of these cells closely corre-
late with disease stage and tumor progression. The
decrease in circulating DCs may have functional conse-
quences on the production of cytokines and on antigen
presentation to naive T-cells. The reason for the
decreased frequency of these two subsets of DCs in
patients with CC remains unknown. It may be that
tumors induce apoptosis in DCs by direct contact, or
tumors may inhibit the differentiation of DCs in vivo by
secreting soluble factors.
Several studies have demonstrated that DCs in tumor
patients are not able to induce primary T-cell responses.
Antigen-specific Treg cells were over-represented at
tumor sites and mediated antigen-specific, local, immune
suppression, thus inhibiting the function of anti-cancer T
effector cells [37,38]. We showed that the DCs upregu-
lated their MHC class II molecules (HLA-DR) in
response to tumor-associated antigens, although DCs
from patients with CC and CIN exhibit more upgraded
HLA-DR than controls. However, the level is moderated,
which is different from other studies(29,36). Lee et al.
found that in women with human papillomavirus (HPV)-
related cervical squamous intraepithelial lesions (SILs) or
atypical squamous cells of undetermined significance
(ASCUS), peripheral blood DC1 and monocyte-derived
dendritic cells (MDDCs), but not DC2 cells, expressed
low levels of HLA-DR [39]. In our study, there is no sig-
nificant difference in HLA-DR between the CIN groups
and the controls, but in the CC group, the expression of
HLA-DR increased. HPV DNA is found in 90% of all cer-
vical cancers. DC2 can be activated by this virus, which
causes them to undergo maturation. This process
enhances their antigen presentation potential by upregu-
lating MHC class II molecules. However, even in fully
mature DC2 cells, levels of MHC II and costimulatory
molecules remain significantly lower than in DC1 cells
[40]. This may be the reason that the expression of HLA-
DR increased and the level is moderated. In addition, all
circulating dendritic cell subsets exhibited low CD80 and
CD86 expression, which is concordant with other reports
Figure 3 The functional immunophenotypings of DCs in patients with CC, CIN and controls.











+/$'5 &' &'
QRUPDO
&,1
&&
Table 3: The serum cytokines secretion in patients with CC, CINII-III and controls
Normal (n = 62) CINII-III (n = 54) CC (n = 37) P
IL-6 ( pg/ml) 11.29 ± 6.36 18.19 ± 12.58 23.67 ± 11.36 0.000* 0.000** 0.013***
TGFβ ( ng/ml ) 5.60 ± 4.83 6.41 ± 5.20 18.22 ± 12.18 0.598* 0.000** 0.000***
IL-10 ( pg/ml ) 52.69 ± 28.27 57.95 ± 32.94 60.18 ± 29.92 0.358* 0.243** 0.735***
VEGF ( pg/ml ) 25.54 ± 19.13 27.92 ± 19.13 30.39 ± 24.19 0.365* 0.436** 0.976***
*Normal vs CINII~III; ** Normal vs CC; *** CINII~III vs CC
P of the three groups:IL-6: P = 0.000, F = 17.712; TGFβ: P = 0.000, F = 21.671;
IL-10: P = 0.450, F = 0.802; VEGF: P = 0.601, F = 0.511Ye et al. Journal of Experimental & Clinical Cancer Research 2010, 29:78
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[29,41]. Our data confirm that in cancer patients, DCs
display an 'immature' phenotype with lower levels of
accessory signals for T cell activation such as CD80 and
CD86 than those expressed on DCs from normal healthy
controls. This may reduce their ability to stimulate T
cells. The antitumor effect of DCs is dependent on their
level of activation and maturation. Lack of costimulatory
molecules in the presence of TCR occupancy leads to T
cell tolerance.
Several studies have demonstrated the effects of indi-
vidual tumor-derived or tumor-induced cytokines on DC
function as they relate to the immune response to malig-
nant tumors [42]. In our study, higher levels of all cytok-
ines under investigation, especially TGFβ and IL-6, were
detected in patientsâ€™ sera compared to controls. This
is inversely correlated with circulating DC1 and DC2,
indicating a possible effect of these cytokines on DCs.
TGFβ and IL-6 are closely related to the invasion and
metastasis of canc er . T hey t hus migh t pla y pivotal but
opposing roles in the host tumor interaction that,
together with other immunomodulating components,
determines the outcome for the development of local
tumor immunity [43]. Many studies in vitro indicate that
these tumor-derived regulatory cytokines have been
shown to inhibit DC development and to impair DC
function[27,29,41,44]. DCs generated in vitro from pro-
genitors purified from cancer patients are capable of
stimulating T-cell responses, but blood DCs isolated from
the same patients are deficient in their APC capac-
ity[27,45]. Our study indicates that the defect in circulat-
ing DC from cervical carcinoma could, at least in part, be
the result of decreased frequency of competent DC and
the accumulation of immature cells with poor APC func-
tion. Tumors may also inhibit circulating DCs by secret-
ing immunosuppressive cytokines.
In summary, we showed that the two subsets of DCs in
PB of patients with cervical carcinoma are significantly
reduced, and that this decrease correlates with an
increase in tumor-derived regulatory cytokines. The find-
ings reported here are relevant due to the large effort
devoted to harnessing blood DCs for the immunotherapy
of cancer. Our data should also be taken into account
when assessing immune competence, as it suggests that it
might not be appropriate to use the peripheral blood DC
compartment as a source of cells for DC-based cancer
immunotherapy protocols.
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